

Colorectal cancer test gets CE-IVD mark, 11/17

November 2017—IntegraGen announced the CE-IVD marking and commercial launch of its miRpredX 31-3p test kit in the European Union.

The miRpredX 31-3p test is a positive theranostic test for patients with metastatic colorectal cancer. It is available as a simple, ready-to-use kit designed to quantify the expression of the miR-31-3p in formalin-fixed, paraffin-embedded tumor samples using standard quantitative reverse transcription PCR. The miRpredX 31-3p test predicts the potential clinical benefits associated with first-line anti-EGFR therapy compared with anti-VEGF therapy, or when second or further lines of treatment with anti-EGFR therapy is beneficial versus chemotherapy alone for patients with RAS wild-type mCRC.

[***IntegraGen***](#), 877-992-7475